Clerkenwell Clinics Ltd

Starting on May 27 in London, this practitioner program is designed for healthcare professionals and students in professional training who are interested in delving into the psychedelic-assisted therapy area. The course aims to equip participants with the necessary knowledge to safely, ethically, and effectively administer psychedelic treatments within a regulated healthcare environment. Upon completion of the programme, graduates will have the opportunity to advance to the certificate programme, a practical training course designed to enhance their skills and understanding for delivering psychedelic-assisted therapy in clinical trials or licensed medical practice. The foundations programme offers a good opportunity for professionals to learn from the forefront of psychedelic research in the UK, with Clerkenwell Health leading nearly half of the ongoing phase 2 clinical trials in the global psychedelic market. Dr Iain Jordan, clinical director at Clerkenwell Health said: “A growing evidence base in research, as well as changes in the law in Australia and possibly in the US soon too, has led to a growing recognition of the role psychedelics could play in improving care for people with mental health problems.” “This training programme is a science- and experience-led, evidence-based curriculum for healthcare professionals to learn more about the theoretical foundation for psychedelic practice, but also the potential risks and harms, as well as the limitations of the current research literature.” googletag.cmd.push(function () { googletag.display('text-ad1'); }); Participants will have the opportunity to learn from a host of world-leading psychedelic experts, including Sara Tai, David Luke, and Jules Evans, among others. The foundations programme spans 30 hours of self-directed online learning over two months, with a course fee of £500. Participants will explore topics such as a transdiagnostic understanding of mental disorders, evidence and mechanisms of psychotherapy, phenomenology and proposed mechanisms of psychedelic treatments, limitations of psychedelic research, Clerkenwell Health’s approach, perspectives from patients and groups, as well as risks, harms, and ethical and legal issues around psychedelic treatments. The resurgence of psychedelic medicine in today's pharmaceutical landscape is marked by a growing interest in the therapeutic potential of psychedelic substances for mental health disorders. Over the past decade, there has been a notable expansion in research exploring the therapeutic effects of psychedelics such as psilocybin, LSD, MDMA (commonly known as ecstasy), and ketamine. Clinical studies have shown promising results in the treatment of conditions like depression, post-traumatic stress disorder (PTSD), addiction, and anxiety. The US Food and Drug Administration (FDA) has granted breakthrough therapy designations to some psychedelic-assisted therapies, expediting their development and review process. For example, MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for treatment-resistant depression are currently in late-stage clinical trials. A variant of LSD has recently received breakthrough therapy designation from the FDA for the treatment of generalized anxiety disorder. This classification comes after a meticulously crafted drug trial, wherein approximately half of the patients administered the drug experienced notable alleviation of their symptoms. The FDA's breakthrough therapy designation expedites the development and assessment of medications hoping to address severe conditions where preliminary data suggests their potential superiority over existing treatments. This accelerated pathway could potentially pave the way for FDA endorsement of LSD in managing generalized anxiety disorder within the coming years. Such approval would inherently authorize the clinical utilization of LSD. There's been a surge in investor interest in psychedelic medicine startups and companies. Venture capital firms, as well as individual investors, are recognizing the potential of these therapies, and are providing funding for research and development. The resurgence of psychedelic medicine in today's pharmaceutical landscape represents a significant shift in mental healthcare, with the potential to offer new and effective treatment options for individuals suffering from various mental health conditions.

The trial, already underway at King's College London, will now expand to include Clerkenwell Health's research facility near Harley Street, London. It is focusing on evaluating the safety, tolerability, and pharmacodynamic effects of a novel psychedelic compound, BPL-003, in combination with psychological support tailored for AUD patients. BPL-003, a synthetic formulation of mebufotenin (5-MeO-DMT), promises shorter yet intense psychedelic experiences, offering a new avenue for treatment. The trial aims to follow participants for 12 weeks post-dosing, conducting multiple assessments to gauge safety, pharmacokinetics, and efficacy. Alarming statistics underline the urgency of finding effective treatments for AUD. According to NHS figures, over 7.5 million people in the UK exhibit signs of alcohol dependence. Public Health England data further reveals the toll of alcohol-related issues, with nearly 21,000 alcohol-related deaths in England in 2021 alone and over 340,000 hospital admissions attributable to alcohol from 2021 to 2022. Dr Henry Fisher, chief scientific officer at Clerkenwell Health, stressed the need for innovative approaches. He said: “Conventional treatments for alcohol dependency aren't producing meaningful improvements, and new avenues must be explored.” He emphasized the potential of psychedelic-assisted treatment to address this pressing public health concern. The trial marks a significant departure from traditional approaches to substance abuse disorder treatment. By combining psychological support with a psychedelic compound under controlled conditions, researchers aim to pioneer a new paradigm in mental health care. googletag.cmd.push(function () { googletag.display('text-ad1'); }); As interest in psychedelic-assisted therapy grows, Clerkenwell Health and Beckley Psytech are aiming to continue to stand at the forefront, using modern and inventive research to redefine mental health treatment. Their collaboration represents a beacon of hope for millions affected by AUD and underscores the potential of innovative therapies to address complex mental health challenges. Dr Rob Conley, chief medical and scientific officer at Beckley Psytech, said: “We're committed to developing a transformative and effective treatment option for individuals struggling with alcohol use disorder. Based on our preclinical and Phase I data, we are optimistic about the potential therapeutic benefits of BPL-003 for substance use disorders and we are excited to evaluate the compound further in this clinical trial. “I want to extend my thanks to the team at Clerkenwell Health and King’s, as well as to the patients who have joined and will join this study. Their participation, support, and collaboration are absolutely critical to furthering research into this area of huge unmet need.” Clerkenwell Health specializes in modern mental health treatments, while Beckley Psytech is dedicated to transforming psychedelics into effective clinical medicines. Both entities say they are going to bring together expertise and resources to lead new approaches to mental health care, saying they want to continue offering hope for a brighter future for individuals and communities affected by neuropsychiatric disorders.

The trial, already underway at King's College London, will now expand to include Clerkenwell Health's research facility near Harley Street, London. It is focusing on evaluating the safety, tolerability, and pharmacodynamic effects of a novel psychedelic compound, BPL-003, in combination with psychological support tailored for AUD patients. BPL-003, a synthetic formulation of mebufotenin (5-MeO-DMT), promises shorter yet intense psychedelic experiences, offering a new avenue for treatment. The trial aims to follow participants for 12 weeks post-dosing, conducting multiple assessments to gauge safety, pharmacokinetics, and efficacy. Alcohol dependence Alarming statistics underline the urgency of finding effective treatments for AUD. According to NHS figures, over 7.5 million people in the UK exhibit signs of alcohol dependence. Public Health England data further reveals the toll of alcohol-related issues, with nearly 21,000 alcohol-related deaths in England in 2021 alone and over 340,000 hospital admissions attributable to alcohol from 2021 to 2022. Dr Henry Fisher, chief scientific officer at Clerkenwell Health ​, stressed the need for innovative approaches. He said: “Conventional treatments for alcohol dependency aren't producing meaningful improvements, and new avenues must be explored.” He emphasized the potential of psychedelic-assisted treatment to address this pressing public health concern. The trial marks a significant departure from traditional approaches to substance abuse disorder treatment. By combining psychological support with a psychedelic compound under controlled conditions, researchers aim to pioneer a new paradigm in mental health care. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Interest in psychedelics growing As interest in psychedelic-assisted therapy grows, Clerkenwell Health ​ and Beckley Psytech are aiming to continue to stand at the forefront, using modern and inventive research to redefine mental health treatment. Their collaboration represents a beacon of hope for millions affected by AUD and underscores the potential of innovative therapies to address complex mental health challenges. Dr Rob Conley, chief medical and scientific officer at Beckley Psytech, said: “We're committed to developing a transformative and effective treatment option for individuals struggling with alcohol use disorder. Based on our preclinical and Phase I data, we are optimistic about the potential therapeutic benefits of BPL-003 for substance use disorders and we are excited to evaluate the compound further in this clinical trial. “I want to extend my thanks to the team at Clerkenwell Health ​ and King’s, as well as to the patients who have joined and will join this study. Their participation, support, and collaboration are absolutely critical to furthering research into this area of huge unmet need.” Clerkenwell Health specializes in modern mental health treatments, while Beckley Psytech is dedicated to transforming psychedelics into effective clinical medicines. Both entities say they are going to bring together expertise and resources to lead new approaches to mental health care, saying they want to continue offering hope for a brighter future for individuals and communities affected by neuropsychiatric disorders. For anyone interested in signing up for a trial, click the patients page link here ​.